Bain Capital Life Sciences, a private equity investment firm, led a $250m Series D funding round in Emalex Biosciences, a developer of biopharmaceutical drugs, with participation from Paragon Biosciences, Valor Equity Partners and Fidelity Management & Research Company. "Emalex was founded specifically to tackle serious neurological conditions like Tourette Syndrome, recognizing that drug development for neurologic conditions is exceptionally difficult and few companies are willing to invest in bringing new options to these patients. Our team has a strong track record of success developing neurology drugs and we are pleased to partner with our investors to advance ecopipam for patients," Jeff Aronin, Emalex Founder.